PAG
TCON

Private Advisor Group’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Private Advisor Group’s Portfolio TCON Stock Details TCON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-50
Closed -$23K – 1473
2018
Q1 		$23K Buy
+50
New +$27.3K ﹤0.01% 1139

Other funds holding TCON

PCM
Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Private Advisor Group's TCON Position: Q2 2018 in Review

Private Advisor Group sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q2 2018, closing a stake of 50 shares — an estimated $23K sold.

Private Advisor Group first reported a position in TCON in Q1 2018 and held it in 1 quarter. The position peaked at $23K in Q1 2018. 33 funds tracked by Wall St. Rank hold TCON as of Q2 2018.

  • Private Advisor Group reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Private Advisor Group sold 50 TRACON Pharmaceuticals, Inc. Common Stock shares in Q2 2018, an estimated $23K.
  • Private Advisor Group first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q1 2018 and held it in 1 quarter.
  • Private Advisor Group's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $23K in Q1 2018.
  • 33 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q2 2018.

Based on Private Advisor Group's 13F filing for Q2 2018, filed 9 Aug 2018.